Buffett Dumps $982 Million in BofA Stock—What Does He Know?

Buffett's been eerily quiet about his reasons, but his actions speak volumes. When someone with his track record starts pulling out of the market, it's time to pay attention.

Get your FREE, no-obligation Wealth Protection Guide now

Michael John Tomsicek net worth and biography

Michael Tomsicek Biography and Net Worth

CFO of CRISPR Therapeutics

Mr. Michael Tomsicek has served as our Chief Financial Officer since November 2017. He brings significant experience in corporate finance, operations management systems and corporate collaborations and licensing. Prior to joining our company, Mike served as Chief Financial Officer of Abiomed, a publicly-traded provider of medical devices, from July 2015 to August 2017. Before that, he was Chief Financial Officer at Cubist Pharmaceuticals. He was at Cubist from August 2010 to January 2015, through the company’s sale to Merck, and held a series of roles of increasing responsibility leading finance, investor relations and strategic sourcing through a period of dynamic growth. Prior to Cubist, Mike spent nearly eight years at General Electric Healthcare, ultimately as Chief Financial Officer of the global ultrasound business. Mike holds an M.B.A. and a B.S. in Engineering, both from the University of Wisconsin.

What is Michael John Tomsicek's net worth?: The estimated net worth of Michael John Tomsicek is at least $1.29 million as of August 6th, 2021. Mr. Tomsicek owns 26,891 shares of CRISPR Therapeutics stock worth more than $1,287,541 as of November 23rd. This net worth estimate does not reflect any other investments that Mr. Tomsicek may own. Learn More about Michael John Tomsicek's net worth.
How do I contact Michael John Tomsicek?: The corporate mailing address for Mr. Tomsicek and other CRISPR Therapeutics executives is BAARERSTRASSE 14, ZUG V8, CH-6300. CRISPR Therapeutics can also be reached via phone at (141) 561-3277 and via email at [email protected]. Learn More on Michael John Tomsicek's contact information.
Has Michael John Tomsicek been buying or selling shares of CRISPR Therapeutics?: Michael John Tomsicek has not been actively trading shares of CRISPR Therapeutics over the course of the past ninety days. Most recently, Michael John Tomsicek sold 25,000 shares of the business's stock in a transaction on Friday, August 6th. The shares were sold at an average price of $138.52, for a transaction totalling $3,463,000.00. Following the completion of the sale, the chief financial officer now directly owns 26,891 shares of the company's stock, valued at $3,724,941.32. Learn More on Michael John Tomsicek's trading history.
Who are CRISPR Therapeutics' active insiders?: CRISPR Therapeutics' insider roster includes Bradley Bolzon (Director), Julianne Bruno (COO), Kurt Emster (Director), Tony Ho (VP), James Kasinger (General Counsel), Lawrence Klein (COO), Samarth Kulkarni (CEO), Rodger Novak (President), Raju Prasad (CFO), and Michael Tomsicek (CFO). Learn More on CRISPR Therapeutics' active insiders.
Are insiders buying or selling shares of CRISPR Therapeutics?: In the last year, insiders at the sold shares 14 times. They sold a total of 192,740 shares worth more than $12,514,312.47. The most recent insider tranaction occured on November, 11th when CEO Samarth Kulkarni sold 30,000 shares worth more than $1,668,600.00. Insiders at CRISPR Therapeutics own 4.1% of the company. Learn More about insider trades at CRISPR Therapeutics.
Information on this page was last updated on 11/11/2024.

Michael John Tomsicek Insider Trading History at CRISPR Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
8/6/2021	Sell	25,000	$138.52	$3,463,000.00	26,891
9/1/2020	Sell	12,000	$92.26	$1,107,120.00	12,410

Michael John Tomsicek Buying and Selling Activity at CRISPR Therapeutics

CRISPR Therapeutics Company Overview

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.

Today's Range

Now: $47.88

$45.85

$48.00

50 Day Range

MA: $47.98

$44.90

$54.86

2 Week Range

Now: $47.88

$43.42

$91.10

Volume

1,504,257 shs

Average Volume

1,903,238 shs

Market Capitalization

$4.09 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.67